Introduction
Hepatic hydrothorax is defined as significant pleural effusion that develops in a patient with liver cirrhosis without cardiopulmonary disease [1] .
In most cases, it is right sided and associated with ascites [2] . The ascitic fluid is drawn to the pleural space by negative intrathoracic pressure through the multiple natural diaphragmatic defects [3] . Analysis of the pleural fluid shows characteristics similar to abdominal ascites [4] .
The goal of treatment of hepatic hydrothorax is relief of symptoms and prevention of complications [5] . The first step in the management is restriction of salt diet, diuretics, and then thoracentesis. Repetitive thoracentesis always carries a risk of severe pain, pneumothorax, and contamination [6] .
For patients with recurrent large volume hydrothorax, failure of previous management, and not candidate for liver transplantation, chest drainage along with chemical pleurodesis is the management of choice as good palliation for these patients [7] . Pleurodesis can be done by many chemicals such as talc, tetracycline derivatives, bleomycin and others; their availability and variable results and adverse effects are still major concerns [8, 9] . Small pigtail catheter is less invasive than ordinary chest tube, and also it is painless, malleable, and easy to insert [10] .
Tigecycline is the first drug in the classes of tetracyclines that is available for intravenous infusion with broader spectrum cover. Its structure is very similar to minocycline and also binds to the bacterial 30S ribosome unit. The most important difference between tigecycline and minocycline is the addition of an N,N-dimethylglycylamido group.
Tetracycline galactosidase has pharmacokinetic distinction consistent with increased concentration and distribution in human tissue. This indicates tigecycline penetrates with higher concentration in the pleural cavity [10] . Bleomycin is a cytotoxic drug, used mainly in recurrent malignant pleural effusion; it is secreted unchanged in urine, and its dose should be reduced in case of renal failure [11] .
Approximately 45% of bleomycin infused into pleural cavity enters the bloodstream, thus exposing patients to systemic adverse effects of bleomycin such as cutaneous and mucosal lesions [12] . In this study, we demonstrated the safety and effectiveness of new chemical pleurodesis drug, tigecycline, in patients with hepatic hydrothorax, not candidates for liver transplantation.
Patients and methods
This randomized controlled clinical study was carried out on 40 patients between January 2017 and August 2017 admitted to the Chest Department, Zagazig University Hospitals. After approval from IRB (Institutional Review Board) Zagazig University, and informed consent was obtained from all the subjects.
According to Child classification, all patients were within Child class B.
Inclusion criteria
The following were the inclusion criteria:
(1) Moderate or massive right-sided pleural effusion.
(2) Mild or moderate ascites.
(3) Albumin more than 2.8. (4) PT prolongation 4.6. (5) Recurrent right-side effusion. (6) Transudate effusion. (7) No renal impairment. (8) No malignancy. (9) Hepatic encephalopathy less than grade II.
Exclusion criteria
The following were the exclusion criteria:
(1) Mild or mild to moderate right-sided hydrothorax.
(2) Massive ascites. The patients were divided into two groups:
(1) Group A: pleurodesis with tigecycline (n=20).
(2) Group B: pleurodesis with bleomycin (n=20).
Technique

Pigtail catheter
Size of pigtail was 12.14.
(1) It was inserted in right 5th mid axillary line (MAL), intercostal tube (ICT). 
Time of pleurodesis
(1) If drain less than 500 ml per 24 h.
(2) Chest radiography shows no effusion or obliteration of costophrenic angles.
Technique of pleurodesis
Group A (tigecycline): the dose used was 2 mg/kg.
First, 30-ml lidocaine diluted in 100 ml normal saline is injected before tigecycline injection by 0.5 h and ask patient to rotate in different body position.
Then, tigecycline is diluted in 100 ml of normal saline and injected in pigtail catheter and closed for 6 h. Then, pigtail catheter is open, left open for 2 h, and then removed.
Group B (bleomycin):
Overall, 30 ml of lidocaine 1% diluted in 100-ml normal saline is injected first. Then, after 0.5 h, bleomycin 60 mg diluted in 100-ml normal saline is injected in pigtail and closed for 6 h and then reopened and removed.
Statistical analysis
Continuous variables were expressed as the mean±SD, and the categorical variables were expressed as a number (percentage There was no significant difference between the two groups regarding age, and sex ( Table 1 ).
The mean age was 46.45±5.82 versus 47.52±5.39 years in group A and group B, respectively. In group A and group B, male patients were 13 (65%) and 14 (70%), respectively.
Presenting symptoms and radiological features of the studied groups are shown in ( Table 2 ). The main symptoms in our patients were dyspnea (100% in both groups) and chest pain (60% in group A versus 65%) in group B), with no significant differences between both groups.
Degree of ascites and pleural effusion in both groups showed no significant differences ( Table 2 , Figures 1-3 ).
There is a significant difference between both groups in relation to adverse effects of pleurodesis material (Table 3 ). Adverse effects of bleomycin were higher than tigecycline in form of pain during instillation, fever, nausea and vomiting, and delayed pain. There is a significant difference between both groups in relation to adverse effects of pleurodesis material (Table 3) .
Regarding follow-up, chest radiography was done for the studied groups at the time of removal of pigtail catheter, after 48 h, after 1 week and after 1 month of pigtail removal. There was no significant difference between both groups. However, after 3 months of removal of pigtail catheter, there was a significant difference in follow-up chest radiography in both groups (Table 4 ).
After 6 months of removal of pigtail catheter, there was a significant difference in follow-up chest radiography in both groups (Table 4 ).
Discussion
Patients with hepatic hydrothorax have poor prognosis, and the goal of the management is palliative treatment to relieve symptoms and prevent complications [1, 2] . Insertion of chest tube for drainage of hepatic hydrothorax is associated with high output drainage with marked fluid and electrolyte depletion, renal failure, impaired immunological function, and death, Chest X-ray of the same patient showing pigtail catheter in place with no effusion.
Figure 3
Tigeycycline ampule. Data are presented as n (%).
Figure 1
Chest X-ray showing right sided moderate pleural effusion (hepatic hydrothorax).
so insertion of chest tube in those patients is a relative contraindication [13] .
Chest tube insertion is also associated with high incidence of pleurocutaneous fistula, which continues to discharge for long time [14] . Pigtail catheter was used in draining many types of pleural effusion including hepatic hydrothorax in different studies [15] . A study by El-Raiding et al. [14] used central venous catheter for draining hepatic hydrothorax with accepted results.
The use of small-bore catheter in draining most types of pleural effusion was studied with good results [16] . The agreement about pleurodesis in patients with hepatic hydrothorax carries some controversies. The chance of failure of pleurodesis could be expected to be high owing to rapid reaccumulation of pleural fluid from ascitic fluid and inability to make complete apposition between parietal and visceral pleura [17] .
Different sclerosing agents were used in literature in hepatic hydrothorax including doxycycline, bleomycin, OK 432, vibramycin, and talc. Tetracycline is considered the agent of choice because of its safety and less adverse effects, but it is not available in intravenous infusion for human in Egypt. Tigecycline is the first drug of tetracycline that is available for intravenous infusion [18] . We investigated whether tigecycline produces the same pleurodesis effects, and the results were compared with those obtained by bleomycin in the treatment of hepatic hydrothorax. Massive effusion 0 (0) 5 (25) Data are presented as n (%). CPA, costophrenic angle.
In our study after 3 months, complete success was seen in 10 (50%) cases in group A, and in group B, complete response was seen in five (25%) cases, which was statistically different.
After 6-month follow-up of our patients in both groups, patients in group A showed complete response in eight cases, whereas in group B, four patients had complete response (20%), and the difference between the two groups was insignificant statistically (P>0.5).
Our results of bleomycin pleurodesis were comparable to those of a study done by Kessinger and Wigton [19] on 13 patients who were given bleomycin pleurodesis for MPE, and the success rate was 30%. Moreover, they are in agreement with Miller et al. [20] , who compared pleurodesis with erythromycin, talc, doxycycline, and diazepam in a rabbit model and found that doxycycline was the most potent pleural sclerosant. They demonstrated that erythromycin may be an ideal sclerosing agent. It had the advantage of maximal fibrosis with minimal inflammation.
Although doxycycline was the most potent pleural sclerosant, it caused severe local tissue damage.
However, our results of bleomycin pleurodesis were lower than that achieved by Emad and Rezaian [21] , who reported a success rate of 89.4% in 20 patients receiving bleomycin via chest tube. Moreover, our results on bleomycin were lower than those of a study done by Herrington et al. [22] , who evaluated bleomycin as a pleurodesis agent in the treatment of malignant and nonmalignant pleural effusions and refractory pneumothoraces in 27 consecutive patients requiring pleurodesis. Twenty-three of 27 patients were evaluated at 30 days. Six (67%) patients out of nine patients with pneumothoraces achieved a response, and two patients with nonmalignant pleural effusions had a complete response. Of 12 patients with malignant pleural effusion, eight (67%) achieved a complete response. This may be explained by the small sample size of our study.
Moreover, Elnady and Sakr [23] studied the safety and efficacy of thoracoscopic pleurodesis with doxycycline poudorage in malignant pleural effusion, and the results showed that 74.1% of patients had successful pleurodesis. However, these results were higher than that achieved by our study, and this may be owing to the different methodology. A study was done by Daddi et al. [24] investigated whether tigecycline is more effective than talc in inducing pleurodesis in 56 New Zealand rabbits. Significant complications occurred in all tigecycline group. One of tigecycline 25 mg/Kg rabbits and one of tigecycline 50 mg/Kg rabbits died of respiratory distress and of right hemothorax D ascites, respectively.
In the present study, complications were recorded immediately after the procedure till discharge of the patients (Table 3) . Pain was seen at the time of pleurodesis in three (15%) patients of tigecycline group and in 12 (60%) patients of bleomycin group, delayed pain occurred in 10 (50%) patients of bleomycin group and only 5% in tigecycline group, and fever was present in approximately 80% of bleomycin group and 20% of tigecycline group.
There was a significant statistical difference between the groups regarding complications ( Table 4 ).
Our study on pleurodesis using bleomycin had comparable results with that of Herrington et al. [22] where 22 (81%) of 27 patients in their study experienced adverse effects with pleurodesis, with pain (81%) and fever (11%) being the most prevalent.
In a study done by Yilmaz et al. [10] to document two successful tigecycline pleurodesis attempts in patients with decompensated liver cirrhosis, who were not candidates for liver transplantation, there were no detected complications in the short-term or long-term follow-up. They concluded that pleurodesis with tigecycline seems to be effective. In the study by Ong et al. [25] , from a total of 20 patients, fever was observed in four cases and pleuritic pain in two cases after the treatment. In addition, empyema, dyspnea, and death were not found in any patients.
Martínez-Moragón et al. [26] reported presence of pain in 10 (32%) patients, fever in six (19%) patients, and nausea and vomiting in 1 (3%) patient postoperatively [11] . In the study by Zimmer et al. [27] , pain and shortness of breath were scored from zero (absence) to 10 (presence) even with the pain and were compared before and after the treatment.A study was done by Daddi et al. [24] to investigate whether tigecycline is more effective than talc in inducing pleurodesis in 56 New Zealand rabbits. Significant complications occurred in all tigecycline group. One of tigecycline 25 mg/Kg rabbits and one of tigecycline 50 mg/Kg rabbits died of respiratory distress and of right hemothorax D ascites, respectively. Approximately 45% of the bleomycin infused into the pleural cavity enters the bloodstream, thus exposing patients to the systemic adverse effects of bleomycin, such as mucosal and cutaneous lesions, pulmonary disorders (including potentially life-threatening interstitial pneumonia), cardiovascular disorders, and severe anaphylactic reactions [24] .
An advantage of tigecycline pleurodesis is the biodegradability of the molecule, which can be administered several times, reaching a dosage level less than 25 mg/kg. Drawbacks of tigecycline are the severe pain, resistance to analgesics in the 25 and 50 mg/kg tigecycline study groups, and its high commercial price. Further studies are needed to delineate the optimal dosage of intrapleural tigecycline for producing pleurodesis in humans: similarly to the previous pleurodesic experiences with tetracyclines and minocyclines, the initial dosage could be approximately 3-4 mg/kg, might be repeated every 24 h several times, and included among the acceptable toxicity levels (below 25 mg/kg) [24] . In our study, the limitation was the small sample size in each group and another limitation is not taking the pH of the pleural fluid in consideration because it can affect the success of pleurodesis as reported by some authors [10] .
There are not many studies evaluating the role of tigecycline as a sclerosing agent.
Conclusion
In conclusion, pleurodesis with tigecycline is an effective and safe procedure in patients with hepatic hydrothorax. Long-term studies are necessary to define the optimal therapeutic guidelines, effectiveness, and adverse effects.
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